• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Theses
    • Theses - Higher Degree by Research
    • View Item
    • Home
    • Griffith Theses
    • Theses - Higher Degree by Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Transdermal Fentanyl for Pain Management in Cancer Patients

    Thumbnail
    View/Open
    Bista_2015_02Thesis.pdf (5.280Mb)
    Author(s)
    Bista, S R.
    Primary Supervisor
    Haywood, Alison
    Other Supervisors
    Norris, Ross
    Hardy, Janet
    Year published
    2015
    Metadata
    Show full item record
    Abstract
    Moderate to severe pain is common among cancer patients and affects 70–80 % of patients with advanced cancer. We have the means and the knowledge to relieve pain in many patients, but evidence from surveys and observational studies shows that many patients have troublesome or severe pain and do not get adequate relief. Although opioids remain the only class of drug with the ability to ameliorate severe pain, even in developed countries with access to a range of opioids, opioid formulations and adjuvant therapies, pain management is still a major problem in cancer care. As there is a narrow therapeutic window between pain ...
    View more >
    Moderate to severe pain is common among cancer patients and affects 70–80 % of patients with advanced cancer. We have the means and the knowledge to relieve pain in many patients, but evidence from surveys and observational studies shows that many patients have troublesome or severe pain and do not get adequate relief. Although opioids remain the only class of drug with the ability to ameliorate severe pain, even in developed countries with access to a range of opioids, opioid formulations and adjuvant therapies, pain management is still a major problem in cancer care. As there is a narrow therapeutic window between pain control and toxicity, there is also substantial potential for side-effects, and, therefore, current practice when starting patients on fentanyl (an opioid class of drug) is to begin with a low dose and titrate the dose up slowly according to pain response and adverse events. As a consequence, it is often several days before a patient’s pain is controlled. Little is known about how factors such as patient demographics, organ function, effect of enzyme inhibitor/inducer, or the drug delivery system itself influence the pharmacokinetics (PK) of fentanyl in cancer patients. Better methods are required to monitor, individualise and improve opioid dosing.
    View less >
    Thesis Type
    Thesis (PhD Doctorate)
    Degree Program
    Doctor of Philosophy (PhD)
    School
    School of Pharmacy
    DOI
    https://doi.org/10.25904/1912/662
    Copyright Statement
    The author owns the copyright in this thesis, unless stated otherwise.
    Item Access Status
    Public
    Subject
    Transdermal Fentanyl
    Opioids
    Cancer pain medication
    Pharmacokinetics (PK) of fentanyl
    Cancer patients
    Publication URI
    http://hdl.handle.net/10072/365555
    Collection
    • Theses - Higher Degree by Research

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander